Exenatide for Treating Cocaine Use Disorder

NCT04941521 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the medication exenatide can help people with cocaine use disorder complete their treatment plan.

Status Completed The study has finished.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 3 people

Who can join Ages 18–60 · all sexes

Timeline Started 2021-06 · est. completion 2021-11

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT04941521 ↗

Description as written by the study sponsor.

The purpose of this study is to collect information about whether exenatide (Bydureon) may be safe and helpful as a medication treatment for individuals who want to stop using cocaine. Although exenatide (Bydureon) is approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes, it has not been approved by the FDA to treat cocaine use; therefore, it is called an investigational drug.

Treatments tested

Exenatide 2 mg [Bydureon] also known as Bydureon Drug

Exenatide will be purchased commercially as Bydureon® for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 6 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
Drug Counseling Behavioral

Once weekly drug counseling sessions for cocaine use with trained masters-level therapists.

Main thing measured	Feasibility as Assessed by Number of Participants Who Completed Treatment
Sponsor	The University of Texas Health Science Center, Houston
Conditions studied	Cocaine Use Disorder
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04941521 ↗